Skip to content
lifestyle.childcarepartnerships.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Recursion Pharmaceuticals
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
November 3, 2026
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
November 2, 2026
Recursion Appoints Fred Hassan as Chair of the Board
November 2, 2026
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
October 26, 2026
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
October 15, 2026
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
October 15, 2026
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
October 15, 2026
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
August 5, 2026
Recursion to Participate in Upcoming Investor Conferences
August 4, 2026
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
July 31, 2026
1
2
Next Page
→